Tenvie Therapeutics has unveiled with $200 million and the goal of transforming the neurological treatment landscape, nabbing ...

A new company is making its debut with a series A sum that’s sure to make hearts race. | A new company is making its debut ...

Backed by ARCH Venture Partners, F-Prime Capital and Mubadala Capital, the new company will develop a pipeline of ...

“Jami is an industry-leading intellect and advisor to transformational healthcare companies,” said Mark Van Lith, CEO of Guggenheim Securities. “Jami is an important addition to our premier healthcare ...

Advancing a deep pipeline of therapeutics focused on treating neurological, cardiometabolic, and ophthalmic diseases Led by expert R&D leadership team with proven ability to develop therapies for CNS ...

After the successful development of mavacamten and the sale of MyoKardia to BMS in 2020, former executives of the biotech are ...

About a year ago, Tenvie President and Chief Scientific Officer Tony Estrada approached Denali CEO Ryan Watts and others in ...

Tenvie Therapeutics is making hay from an R&D shift at Denali Therapeutics, acquiring several of its neuroscience drug ...

Biotech firm Maze Therapeutics, backed by Third Rock Ventures, revealed a profit for the first nine months of 2024 in its ...

Stanton Williams has been selected to design the Fleming Centre, a state-of-the-art research and public engagement facility ...

In a release issued under the same headline earlier today by HPQ Silicon Inc. , please note that in the 11th paragraph, the number of units issued is not 1,009,343 but 1,083,333. The revised release ...

Kardigan, a heart health company modernizing cardiovascular drug development, launched today with a mission to develop multiple targeted treatments in parallel, bringing people with cardiovascular ...